Study on the efficacy and safety of remimazolam combined with sevoflurane in intubation general anesthesia

Study on the efficacy and safety of remimazolam combined with sevoflurane in intubation general anesthesia: a prospective, single-blinded, randomized and placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200061217

Enrollment

Unknown

Registered

2022-06-15

Start date

2022-06-03

Completion date

Unknown

Last updated

2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesiology

Interventions

Group 1 :Propopol

Group 2:Remimazolam

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-60 years old; 2. ASA I-III level; 3. Surgical patients who are expected to undergo intubation and general anesthesia for no less than 1 hour; 4. After the operation, it is planned to send to the recovery room for resuscitation and extubation of the tracheal tube.

Exclusion criteria

Exclusion criteria: 1. Patients with severe hypertension (systolic blood pressure >= 200 mmHg, or diastolic blood pressure >= 120 mmHg); 2. Patients with difficult airway; 3. Patients with severe heart, liver, lung or kidney disease; 4. Patients with severe anemia, shock, metabolic disease, electrolyte disorder; 5. Pregnant women; patients unable to communicate; alcohol and drug addicts; 6. Patients with gastric retention or delayed gastric emptying; 7. Patients who abuse hormones or narcotic analgesics; 8. Those who are allergic to the drugs studied; 9. High-risk groups with malignant high fever; 10. Controlled step-down or step-up surgery.

Design outcomes

Primary

Measure	Time frame
efficacy;	—

Secondary

Measure	Time frame
safety;	—

Countries

China

Contacts

Public ContactXuehai Guan

First Affiliated Hospital of Guangxi Medical University

guan_xh@aliyun.com+86 18587697310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026